For patients with HER2+ breast cancer with a resectable HER2+ local relapse within 12 months of completion of standard adjuvant therapy including 1 year of trastuzumab, what adjuvant therapy would you recommend?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Her2+ • Moffitt Cancer Center • NCI-CCC Breast Tumor Board Question

Does hormone receptor status impact your decision?

Answer from: Medical Oncologist at Academic Institution

This is an interesting question as it implies likely primary resistance to trastuzumab. First, it depends upon the type of recurrence the patient experienced (ipsilateral, contralateral, chest wall recurrence post-mastectomy or axillary recurrence). Second it depends on the hormone receptor status o...

Comments

Medical Oncologist at Northwest Georgia Oncology Centers
How would you interpret the results from CALOR tri...

Medical Oncologist at Icahn School of Medicine at Mount Sinai
The women who benefited most in the CALOR trial we...

Answer from: Medical Oncologist at Academic Institution

I think an early local recurrence indicates persistent disease and per the results of the Katherine trial, patients with persistent disease after trastuzumab based chemotherapy have a much improved prognosis with TDM-1. I would offer at least 14 doses of this as in the Katherine trial, along with th...

Comments

Medical Oncologist at NYU Winthrop Hospital
I would treat this as persistent disease after tra...

Medical Oncologist at Icahn School of Medicine at Mount Sinai
It's not wrong to consider TDM-1, l just point out...

Related Questions